TRACON Pharmaceuticals, Inc. Announces Results From A Clinical Trial Of TRC105 In Patients With Hepatocellular Carcinoma To Be Presented At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium
Published: Jan 09, 2015
SAN DIEGO, Jan. 9, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced that results from a clinical trial combining TRC105 with Nexavar® (sorafenib) in patients with hepatocellular carcinoma will be presented at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium being held from January 15-17, 2015, in San Francisco.
The presentation details are as follows:
|Abstract Title:||A Phase I/II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma (HCC)|
|Presenter:||Austin G. Duffy, M.D., Center for Cancer Research, National Cancer Institute|
|Session:||General Poster Session B|
|Date:||Friday, January 16, 2015|
|Time:||12:00PM-2:00PM and 5:30PM-7:00PM|
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also expected to be studied in combination with VEGF inhibitor treatments in age-related macular degeneration. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.
TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.CONTACT: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 email@example.com and post your resume.